The artificial trans fats found in fried foods and margarine don’t seem to raise the risk of type 2 diabetes when looked at on their own, which surprises many people who think all trans fats are bad.
Scientific Claim
Industrial trans fatty acids (18:1n-6t, 18:1n-9t, 18:2n-6,9t) are not associated with type 2 diabetes risk when analyzed individually and adjusted for other trans fatty acids, challenging the assumption that all trans fats uniformly increase diabetes risk.
Original Statement
“After controlling for other TFAs, the iTFAs (18:1n-6t, 18:1n-9t, 18:2n-6,9t) were not associated with diabetes risk.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study design supports correlational claims. The authors correctly used 'not associated' and reported null results with confidence intervals crossing 1.0, avoiding causal language.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether industrial TFAs as individual isomers are truly neutral for type 2 diabetes risk across diverse populations.
Whether industrial TFAs as individual isomers are truly neutral for type 2 diabetes risk across diverse populations.
What This Would Prove
Whether industrial TFAs as individual isomers are truly neutral for type 2 diabetes risk across diverse populations.
Ideal Study Design
A meta-analysis of 15+ prospective cohorts using standardized GC-MS to measure plasma 18:1n-9t, 18:1n-6t, and 18:2n-6,9t at baseline, with incident type 2 diabetes confirmed by medical records, adjusting for identical covariates and stratifying by dietary TFA intake levels.
Limitation: Cannot prove causation or rule out residual confounding from food matrix effects.
Prospective Cohort StudyLevel 2bIn EvidenceWhether industrial TFA isomers are neutral for type 2 diabetes in a population with high historical intake.
Whether industrial TFA isomers are neutral for type 2 diabetes in a population with high historical intake.
What This Would Prove
Whether industrial TFA isomers are neutral for type 2 diabetes in a population with high historical intake.
Ideal Study Design
A prospective cohort study of 12,000 adults aged 45–75 in a country with high historical industrial TFA consumption (e.g., pre-ban USA), measuring plasma phospholipid iTFAs via GC-MS at baseline, with 10-year follow-up for incident type 2 diabetes confirmed by HbA1c and medical records.
Limitation: Still observational; cannot isolate TFA effects from other dietary components.
Case-Control StudyLevel 3bWhether plasma industrial TFA levels differ between individuals with and without type 2 diabetes after controlling for diet and lifestyle.
Whether plasma industrial TFA levels differ between individuals with and without type 2 diabetes after controlling for diet and lifestyle.
What This Would Prove
Whether plasma industrial TFA levels differ between individuals with and without type 2 diabetes after controlling for diet and lifestyle.
Ideal Study Design
A matched case-control study of 1,000 individuals with incident type 2 diabetes and 1,000 controls, matched for age, sex, BMI, and diet, with plasma phospholipid iTFAs measured via GC-MS within 6 months of diagnosis.
Limitation: Prone to recall and selection bias; cannot establish temporal sequence.
Evidence from Studies
Supporting (1)
Plasma Industrial and Ruminant Trans Fatty Acids and Incident Type 2 Diabetes in the EPIC-Potsdam Cohort
This study found that certain artificial trans fats (like those in fried foods) didn’t raise diabetes risk when looked at alone, even when other trans fats were considered — meaning not all trans fats are equally bad for you.